

Raffles Medical Group Launches Mastrocheck[®] to Improve Early Breast Cancer Detection

Singapore, 26 September 2022 – Raffles Medical Group (RMG) and Bertis today announced the launch of Mastrocheck[®], a blood-based test to screen for breast cancer. RMG is the first healthcare provider in Singapore to introduce this innovative diagnostic tool.

Mastrocheck[®], developed by South Korea-based Bertis, is the world's first proteomics¹-based early diagnosis solution for breast cancer. It is a convenient method that requires just a small amount of blood for diagnosis.

Asian women tend to have denser breasts, where there are more gland tissue compared to fatty tissue. In such cases, breast tumours may be difficult to detect through a routine mammogram. Mastrocheck[®] can thus be used to supplement the routine mammogram to increase the accuracy of detecting breast cancer early.

In Singapore, breast cancer is the most common cancer among women, and over 2,000 women are diagnosed with breast cancer every year². Detecting breast cancer early is critical as the chances of surviving increases with early detection.

Mastrocheck[®] is highly recommended for women who belong to higher risk group, such as those who have a family history of breast cancer. Women who require a mammogram can also add this supplement test for a more accurate diagnosis.

Mr Han Seung-man, CEO of Bertis, said: "Proteomic technology has the advantage of providing accurate and convenient high-quality tests. We are pleased to partner Raffles Medical Group to introduce Mastrocheck[®] to Singapore to benefit more women here and we will do our best to expand the innovative test availability to other regions, including Asia so that more people can benefit from the proteomic-based diagnostic assay."

"Breast cancer is the most common cancer in women, and early detection can save lives. As part of our continued effort to improve patient care, Mastrocheck[®] is offered at Raffles Hospital, Raffles Breast Centre, Raffles Health Screeners, and all Raffles Medical clinics to serve our patients'

¹ Proteomics is the study of complete protein profile of the given tissue or cell

² Source: Singapore Cancer Society (<https://www.singaporecancersociety.org.sg/learn-about-cancer/types-of-cancer/breast-cancer.html#overview>)

evolving healthcare and wellness needs,” said Dr Chng Shih Kiat, Medical Director of Raffles Medical.

“Many women with early breast cancer have no symptoms. Therefore, regular breast cancer screening is very important especially for those with risk factors and those aged 40 and above. Using a simple blood test to supplement our breast screening programme will certainly be helpful for the early detection of breast cancer,” said Prof Walter Tan, Medical Director of Raffles Hospital.

###

For media queries, please contact:

Joanna Lee

Senior Manager, Corporate Communications

Raffles Medical Group

Email: lee_joanna@rafflesmedical.com

About Raffles Medical Group

Founded in 1976, Raffles Medical Group (RMG or the Group) is one of the leading integrated private healthcare providers in the region, providing a continuum of services from primary and tertiary care to health insurance for people across Asia. A proudly Singaporean brand, RMG is listed on the mainboard of the Singapore stock exchange (SGX: BSL) and operates in 14 cities in five countries in Asia. This network includes four hospitals and over 100 multi-disciplinary clinics, offering services such as health screening, specialist care, diagnostic radiology, dental and traditional Chinese medicine. Together with over 2,700 employees, RMG brings more than 45 years of trusted healthcare expertise and care to over 2 million patients annually across our network as their trusted partner for health. For more information, please visit rafflesmedicalgroup.com.

About Bertis

Bertis is a company that has discovered biomarkers for cancer and other major disorders and provided diagnostic and analysis solutions based on the combination of proteomics and bioinformatics. Since our establishment in 2014, our mission has been to contribute to the health and happy life of mankind through the realization of early diagnosis medicine with a focus on the most advanced quantitative proteomics research, precision medicine based on companion diagnostic markers, and companion diagnostics for oncology drug development and personalized treatment. Our flagship solutions include MASTOCHECK, the world’s first proteomics-based blood test solution for early breast cancer detection, and PASS (Pan-omics Analysis Service & Solution), a platform for integrative analysis of pan-omics (multi-omics) data. For more information, please visit our website www.bertis.com.